Professional
Added to YB: 2024-04-24
Pitch date: 2024-04-08
ILMN [bullish]
Illumina, Inc.
-6.14%
current return
Author Info
No bio for this author
Company Info
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Market Cap
$17.9B
Pitch Price
$127.85
Price Target
253.00 (+111%)
Dividend
N/A
EV/EBITDA
15.33
P/E
21.43
EV/Sales
4.32
Sector
Life Sciences Tools and Services
Category
growth
RBC Capital Markets Investment Thesis: Illumina, Inc.
ILMN: Outperform, $253 PT. Oversold on competition fears, ignores $120B TAM & innovation. Return to DD growth = multiple expansion. 44.5x P/E on $5.69 'core' FY25 EPS (ex-Grail & normalized tax). Risks: Grail impact, R&D cuts, competition, NGS alternatives.
Read full article (2 min)